|
|
|
By Joseph Pategou | Significant regulatory shifts have reshaped the biosimilar landscape and are projected to reach a value of $35.7 billion in 2025 in the global market. See how biosimilars are slated for considerable growth opportunities, thanks in part to clinical regulatory changes. | |
|
|
|
By Daniel Espinoza, Ph.D., Lund University | Developing a downstream process for a new drug candidate is costly due to the high value of the potential drug. Examine a case study in which one researcher simply pressed play on a set of six pre-programmed experiments and returned hours later to a complete data set. | |
|
|
|
By D. Mahajan and S. Govind Donthula, MarketsandMarkets | Pharma and biotech companies are experiencing a rising number of inspection checkpoint mandates, which is leading to an increase in the use of inspection machines with advanced technologies, such as x-ray inspection, robotics, and more, to help them get ahead. | |
|
|
|
|
|
|
|
|
|
|
|
|
|
